Legislation to speed cancer drug development for children and adolescents requires drug companies to test drugs in children, but trials in people under 18 may take years to generate results.

by Marci A. Landsmann

Policy Matters

FOR MORE THAN 25 YEARS,​ the American Association for Cancer Research (AACR) has been building bridges between cancer patient advocates and scientists through unique educational programs that foster communication. In October 2020, the AACR expanded its educational programming by introducing quarterly AACR Virtual Patient Advocate Forums. Available at no cost to patient advocates around the world, […]

by Carrie Treadwell, MBA

A symposium at the AACR Annual Meeting explores how social factors contribute to elevated risk of cancer in some populations.

by Eric Fitzsimmons

Forward Look

Medical oncologist Lola Fashoyin-Aje describes the Food and Drug Administration’s efforts to make clinical trials more inclusive.

by Erin O'Donnell

CAR T-cell therapy effects continue 10 years after treatment and first T-cell receptor therapeutic approved for uveal melanoma.

by Eric Fitzsimmons

From the Editor-in-Chief

Is it the beginning of the end or the end of the beginning?

by William G. Nelson, MD, PhD

Expansions in coverage and eligibility through the Affordable Care Act have made Medicaid a lifeline for many people with cancer, but benefits vary from state to state.

by Sharon Tregaskis

Some cancer centers scrutinized for lack of pricing transparency, and an imaging drug helps surgeons better identify ovarian cancer with fluorescent lighting.

by Marci A. Landsmann

HPV vaccine rates are higher when teens decide, and colorectal cancer is on the rise in people under 50.

by Kevin McLaughlin

Policy Matters

The AACR is engaging with Congress and the Biden administration on the importance of funding for cancer research.

by David A. Tuveson, MD, PhD